Registered number
09004411
Artemida Pharma Ltd
Filleted Accounts
30 April 2024
Artemida Pharma Ltd
Registered number: 09004411
Balance Sheet
as at 30 April 2024
Notes 2024 2023
£ £
Fixed assets
Tangible assets 3 6,242 8,322
Investments 4 151 151
6,393 8,473
Current assets
Debtors 5 84,750 119,082
Cash at bank and in hand 65,796 63,912
150,546 182,994
Creditors: amounts falling due within one year 6 (20,858) (52,134)
Net current assets 129,688 130,860
Net assets 136,081 139,333
Capital and reserves
Called up share capital 76 76
Profit and loss account 136,005 139,257
Shareholders' funds 136,081 139,333
The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
Robert Miller
Director
Approved by the board on 13 January 2025
Artemida Pharma Ltd
Notes to the Accounts
for the year ended 30 April 2024
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Fixtures, fittings, tools and equipment 25% on reducing balance
Investments
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Current and deferred tax assets and liabilities are not discounted.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Pensions
Contributions to defined contribution plans are expensed in the period to which they relate.
2 Employees 2024 2023
Number Number
Average number of persons employed by the company 2 2
3 Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 May 2023 28,237
At 30 April 2024 28,237
Depreciation
At 1 May 2023 19,915
Charge for the year 2,080
At 30 April 2024 21,995
Net book value
At 30 April 2024 6,242
At 30 April 2023 8,322
4 Investments
Investments in
subsidiary
undertakings
£
Cost
At 1 May 2023 151
At 30 April 2024 151
Subsidiary Undertakings
The following were subsidiary undertakings of the Company:
Name Country of incorporation Class of share Holding Principle activities
Artemida Pharma Europe Ltd Ireland 100 Ordinary shares 100% Pharma Research Consultancy
of Euro 1 each
The aggregate of the share capital and reserves as at 30 April 2024 and of the profit or loss for the year ended on that date for the subsidiary undertakings were as follows:
Aggregate of shares capital and reserves
Euro
Artemida Pharma Europe Ltd (1,473)
5 Debtors 2024 2023
£ £
Trade debtors 24,767 44,995
Other debtors 59,983 74,087
84,750 119,082
6 Creditors: amounts falling due within one year 2024 2023
£ £
Bank loans and overdrafts 704 706
Trade creditors 9,551 27,090
Amounts owed to group undertakings and undertakings in which the company has a participating interest (23,089) (23,051)
Taxation and social security costs 6,538 17,582
Other creditors 27,154 29,807
20,858 52,134
7 Controlling party
The ultimate controlling parties are the Directors jointly.
8 Other information
Artemida Pharma Ltd is a private company limited by shares and incorporated in England. Its registered office is:
Stevenage Bioscience Catalyst
Gunnels Wood Road
Stevenage
Hertfordshire
SG1 2FX
Artemida Pharma Ltd 09004411 false 2023-05-01 2024-04-30 2024-04-30 VT Final Accounts April 2024 Robert Miller No description of principal activity 09004411 2022-05-01 2023-04-30 09004411 core:WithinOneYear 2023-04-30 09004411 core:ShareCapital 2023-04-30 09004411 core:RetainedEarningsAccumulatedLosses 2023-04-30 09004411 2023-05-01 2024-04-30 09004411 bus:PrivateLimitedCompanyLtd 2023-05-01 2024-04-30 09004411 bus:AuditExemptWithAccountantsReport 2023-05-01 2024-04-30 09004411 bus:Director40 2023-05-01 2024-04-30 09004411 core:PlantMachinery 2023-05-01 2024-04-30 09004411 countries:England 2023-05-01 2024-04-30 09004411 bus:FRS102 2023-05-01 2024-04-30 09004411 bus:FilletedAccounts 2023-05-01 2024-04-30 09004411 2024-04-30 09004411 core:WithinOneYear 2024-04-30 09004411 core:ShareCapital 2024-04-30 09004411 core:RetainedEarningsAccumulatedLosses 2024-04-30 09004411 core:PlantMachinery 2024-04-30 09004411 2023-04-30 09004411 core:PlantMachinery 2023-04-30 iso4217:GBP xbrli:pure